Snapshot from Jul 07, 2026 at 07:00 UTC. For live data and tracking: View Live
Entity

AnBogen Therapeutics

Tracked across 4 events · 24 articles · First seen Jan 17, 2026 · Last active Jul 01, 2026

Sentiment
38
Attention
4
Events
4
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
4 70
Tech
Impact: AnBogen Therapeutics announced two key research abstracts for its lead compound, Imofinostat (ABT-301), demonstrating its potential in enhancing immunotherapy for colorectal cancer and overcoming chemotherapy resistance in pancreatic cancer. The company is also advancing a Phase 1/2 clinical trial and plans for an Emerging Stock Market listing.
Apr 13, 2026 · 6 articles
3 70
Business
Impact: AnBogen Therapeutics engaged two consulting firms to advance its lead candidate, PT-00114, into Phase 2 clinical studies, which is expected to strengthen its operational processes and regulatory strategy.
May 19, 2026 · 6 articles
1 10
Business
Impact: AnBogen Therapeutics granted inducement awards to three new employees, consisting of stock options and restricted stock units, as a material inducement for their employment. This action aims to attract and retain talent, which is generally positive for the company's long-term prospects.
Jun 16, 2026 · 6 articles
2 0
Business
Jan 17, 2026 · 6 articles
100 AnBogen Therapeutics granted inducement awardsProtagonist Therapeutics...
ERGEN INTELLIGENCE
Track AnBogen Therapeutics live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.